In vitro mutagenicity and blood compatibility of paclitaxel and curcumin in poly (dl-lactide-co-glicolide) films

Toxicology in Vitro

Volumn 27, Issue 1, 2013, Pages 198-203

  Vieira, Iara Lucia Barbosa Fernandes ^a   de Souza, Debora Cristina Passos ^a   da Silva Coelho, Liliane ^b   Chen, Lee Chen ^a   Guillo, Lidia Andreu ^a  

^a FEDERAL UNIVERSITY OF GOIÁS   (Brazil)

^b UNIVERSIDADE ESTADUAL DE GOIÁS   (Brazil)

Author keywords

Curcumin; Fibrinogen adsorption; Mutagenicity; Platelet activation; Poly (dl lactide co glycolide) films; Stents

Indexed keywords

CURCUMIN; FIBRINOGEN; PACLITAXEL; PADGEM PROTEIN; POLYGLACTIN; RAPAMYCIN;

ADSORPTION KINETICS; AMES TEST; ARTICLE; BACTERIAL COLONIZATION; BACTERIAL STRAIN; BIOCOMPATIBILITY; BLOOD COMPATIBILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFECT; HUMAN; HUMAN CELL; IN VITRO STUDY; MUTAGENICITY; NONHUMAN; PROTEIN EXPRESSION; SALMONELLA TYPHIMURIUM; THROMBOCYTE ACTIVATION; TOXICITY TESTING;

ADSORPTION; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CURCUMIN; DRUG-ELUTING STENTS; FIBRINOGEN; HUMANS; LACTIC ACID; MUTAGENICITY TESTS; MUTAGENS; PACLITAXEL; PLATELET ACTIVATION; POLYGLYCOLIC ACID; SALMONELLA TYPHI; SIROLIMUS;

BACTERIA (MICROORGANISMS);

EID: 84869433333     PISSN: 08872333     EISSN: 18793177     Source Type: Journal    
DOI: 10.1016/j.tiv.2012.10.013     Document Type: Article

References (51)

1. Aggarwal B.B., Harikumar K.B. Potential therapeutic effects of curcumin, the anti-inflammatory agent against neurodegenerative, cardiovascular, pulmonary, metabolic, autoimmune and neoplastic diseases. Int. J. Biochem. Cell Biol. 2009, 41:40-59.
2. Akin I., Schneider H., Ince H., Kische S., Rehders T.C., Chatterjee T., et al. Second- and third-generation drug-eluting coronary stents. Progress and safety. Herz 2011, 36:190-197.
3. Anto R.J., George J., Babu K.V.D., Rajasekharan K.N., Kuttan R. Antimutagenic and anticarcinogenic activity of natural and synthetic curcuminoids. Mutat. Res. 1996, 370:127-131.
4. Anuchapreeda S., Tima S., Duangrat C., Limtrakul P. Effect of pure curcumin demethoxycurcumin, and bis-demethoxycurcumin on WT1 gene expression in leukemic cell lines. Cancer Chemother. Pharmacol. 2008, 62:585-594.
5. Axel D.I., Kunert W., Göggelmann C., Oberhoff M., Herdeg C., Küttner A., et al. Paclitaxel inhibits arterial smooth muscle cell proliferation and migration in vitro and in vivo using local drug delivery. Circulation 1997, 96:636-645.
6. Bavry A.A., Kumbhani D.J., Helton T.J., Bhatt D.L. What is the risk of stent thrombosis associated with the use of paclitaxel-eluting stents for percutaneous coronary intervention? A meta-analysis. J. Am. Coll. Cardiol. 2005, 45:941-946.
7. Bergström K., Holmberg K., Safranj A., Hoffmam A.S., Edgell M.J., Kozlowski A., et al. Reduction of fibrinogen adsorption on PEG-coated polystyrene surfaces. J. Biomed. Mater. Res. 1992, 26:779-790.
8. Brambilla G., Martelli A. Update on genotoxicity and carcinogenicity testing of 472 marketed pharmaceuticals. Mutat. Res. 2009, 681:209-229.
9. Bridges A.W., García A.J. Anti-inflammatory polymeric coatings for implantable biomaterials and devices. J. Diabetes Sci. Technol. 2008, 2:984-994.
10. Carlsson J., von Wagenheim B., Linder R., Anwari T.M., Qvist J., Petersson I., et al. Is late stent thrombosis in drug-eluting stents a real clinical issue? A single-center experience and review of the literature. Clin. Res. Cardiol. 2007, 96:86-93.
11. Chiumiento A., Lamponi S., Barbucci R. Role of fibrinogen conformation in platelet activation. Biomacromolecules 2007, 8:523-531.
12. Clarke M.L., Wang J., Chen Z. Conformational changes of fibrinogen after adsorption. J. Phys. Chem. B 2005, 109:22027-22035.
13. Cunha K.S., Reguly M.L., Graf U., Andrade H.H.R. Taxanes: the genetic toxicity of paclitaxel and docetaxel in somatic cells of Drosophila melanogaster. Mutagenesis 2001, 16:79-84.
14. Curcio A., Torella D., Indolfi C. Mechanisms of smooth muscle cell proliferation and endothelial regeneration after vascular injury stenting. Circ. J. 2011, 75:1287-1296.
15. Digue L., Orsière T., De Méo M., Mattéi M.G., Depetris D., Duffaud F., et al. Evaluation of the genotoxic activity of paclitaxel by the in vitro micronucleus test in combination with fluorescent in situ hybridization of a DNA centromeric probe and the alkaline single cell gel electrophoresis technique (comet assay) in human T-lymphocytes. Environ. Mol. Mutagen. 1999, 34:269-278.
16. Efeoglu C., Akçay Y.D., Ertürk S. A modified method for preparing platelet-rich plasma: an experimental study. J. Oral Maxillofac. Surg. 2004, 62:1403-1407.
17. EFSA Panel on Food Additives and Nutrient Sources added to Food (ANS) Scientific Opinion on the re-evaluation of curcumin (E-100) as a food additive. EFSA J. 2010, 8:1679-1725.
18. Ellis S.G., Stone G.W., Cox D.A., Hermiller J., O'Shaugnessy C., Mann T., et al. Long-term safety and efficacy with paclitaxel-eluting stents: 5-year final results of the TAXUS-IV clinical trial (TAXUS IV-SR: treatment of de novo coronary disease using a Paclitaxel-Eluting Stent). J. Am. Coll. Cardiol. Interv. 2009, 2:1248-1259.
19. García-García H.M., Vaina S., Tsuchida K., Serruys P.W. Drug-eluting stents. Arch. Cardiol. Mex. 2006, 76:297-319.
20. Granada J.F., Alviar C.L., Bradley-Wallace D., Osteen M., Dave B., Tellez A., et al. Patterns of activation and deposition of platelets exposed to the polymeric surface of the paclitaxel eluting stent. J. Thromb. Thrombolysis 2010, 29:60-69.
21. Hinohara T. Percutaneous coronary intervention: current perspective. Keio J. Med. 2001, 50:152-160.
22. Jang H.S., Nam H.Y., Kim J.M., Hahm D.H., Nam S.H., Kim K.L., et al. Effects of curcumin for preventing restenosis in a hypercholesterolemic rabbit iliac artery stent model. Catheter. Cardiovasc. Interv. 2009, 74:881-888.
23. Jayaprakasha G.K., Rao L.J., Sakariah K.K. Antioxidant activities of curcumin, demethoxycurcumin and bisdemethoxycurcumin. Food Chem. 2006, 98:720-724.
24. Jurenka J.S. Anti-inflammatory properties of curcumin, a major constituent of Curcuma longa: a review of preclinical and clinical research. Altern. Med. Rev. 2009, 14:141-153.
25. Koh L.B., Rodriguez I., Venkatraman S.S. Conformational behavior of fibrinogen on topographically modified polymer surfaces. Phys. Chem. Chem. Phys. 2010, 12:10301-10308.
26. Leon M.B., Mauri L., Popma J.J., Cutlip D.E., Nikolsky E., O'Shaughnessy C., et al. A randomized comparison of the ENDEAVOR zotarolimus-eluting stent versus the TAXUS paclitaxel-eluting stent in de novo native coronary lesions. 12-month outcomes from the ENDEAVOR IV trial. J. Am. Coll. Cardiol. 2010, 55:543-554.
27. Lu L., Garcia C.A., Mikos A.G. In vitro degradation of thin poly(dl-lactic-co-glycolic acid) films. J. Biomed. Mater. Res. 1999, 46:236-244.
28. Maron D.M., Ames B.N. Revised methods for the Salmonella mutagenicity test. Mutat. Res. 1983, 113:173-215.
29. Martinez-Ebal L., Ruiz-Nodar J.M., Zueco J., Lopez-Minguez J.R., Moreu J., Calvo I., et al. Direct coronary stenting versus stenting with balloon predilation: immediate and follow up results of a multicentre, prospective, randomized study. The DISCO trial. Direct stenting of coronary arteries. Eur. Heart J. 2002, 23:633-640.
30. Marx S.O., Jayaraman T., Go L.O., Marks A.R. Rapamycin-FKBP inhibits cell cycle regulators of proliferation in vascular smooth muscle cells. Circ. Res. 1995, 76:412-417.
31. Mortelmans K., Zeiger E. The Ames Salmonella/microsome mutagenicity assay. Mutat. Res. 2000, 455:29-60.
32. Mulky N., Amonkar A.J., Bhide S.V. Antimutagenicity of curcumin and related compounds: the structural requirement for the antimutagenicity of curcumins. Indian Drugs 1987, 25:91-95.
33. Nguyen K.T., Shaikh N., Shukla K.P., Su S.H., Eberhart R.C., Tang L. Molecular responses of vascular smooth muscle cells and phagocytes to curcumin-elutin bioresorbable stent materials. Biomaterials 2004, 25:5333-5346.
34. Nguyen K.T., Su S.H., Sheng A., Wawro D., Schwade N.D., Brouse C.F., et al. In vitro hemocompatibility studies of drug-loaded poly-(l-lactic acid) fibers. Biomaterials 2003, 24:5191-5201.
35. Palmaz J.C., Benson A., Sprague E.A. Influence of surface topography on endothelialization of intravascular metallic material. J. Vasc. Interv. Radiol. 1999, 10:439-444.
36. Pan C.J., Tang J.J., Weng Y.J., Wang J., Huang N. Preparation, characterization and anticoagulation of curcumin-eluting controlled biodegradable coating stents. J. Control. Release 2006, 116:42-49.
37. Pan C.J., Shao Z.Y., Tang J.J., Wang J., Huang N. In vitro studies of platelet adhesion, activation, and protein adsorption on curcumin-eluting biodegradable stent materials. J. Biomed. Mater. Res. A 2006, 82A:740-746.
38. Pfisterer M., Brunner-La Rocca H.P., Rickenbacher P., Hunziker P., Mueller C., Nietlispach F., et al. Long-term benefit-risk balance of drug-eluting vs. bare-metal stents in daily practice: does stent diameter matter? Three-year follow-up of BASKET. Eur. Heart J. 2009, 30:16-24.
39. Poon M., Marx S.O., Galo R., Badimon J.J., Tauban M.B., Marks A.R. Rapamycin inhibits vascular smooth muscle cell migration. J. Clin. Invest. 1996, 98:2277-2283.
40. Rao T.S., Basu N., Siddiqui H.H. Anti-inflammatory activity of curcumin analogues. Indian J. Med. Res. 1982, 75:574-578.
41. Sandur S.K., Pandey M.K., Sung B., Ahn K.S., Murakami A., Sethi G., et al. Curcumin, demethoxycurcumin, bisdemethoxycurcumin, tetrahydrocurcumin and turmerones differentially regulate anti-inflammatory and anti-proliferative responses through a ROS-independent mechanism. Carcinogenesis 2007, 28:1765-1773.
42. Shishu, Kaur I.P. Antimutagenicity of curcumin and related compounds against genotoxic heterocyclic amines from cooked food: the structural requirement. Food Chem. 2008, 111:573-579.
43. Sollot S.J., Cheng L., Pauly R.R., Jenkins G.M., Monticone R.E., Kuzuya M., et al. Taxol inhibits neointimal smooth muscle cell accumulation after angioplasty in the rat. J. Clin. Invest. 1995, 95:1869-1876.
44. Sousa J.E., Costa M.A., Abizaid A., Abizaid A.S., Feres F., Pinto I.M.F., et al. Lack of neointimal proliferation after implantation of sirolimus-coated stents in human coronary arteries: a quantitative coronary angiography and three-dimensional intravascular ultrasound study. Circulation 2001, 103:192-195.
45. Spivak B., Vered Y., Graff E., Blum I., Mester R., Weizman A. Low platelet-poor plasma concentrations of serotonin in patients with combat-related posttraumatic stress disorder. Biol. Psychiatry 1999, 45:840-845.
46. Stone G.W., Ellis S.G., Cox D.A., Hermiller J., O'Shaughnessy C., Mann J.T., et al. A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease. N. Engl. J. Med. 2004, 350:221-231.
47. Su S.H., Nguyen K.T., Satasiya P., Greilich P.E., Tang L., Eberhart R.C. Curcumin impregnation improves the mechanical properties and reduces the inflammatory response associated with poly(l-lactic acid) fiber. J. Biomater. Sci. Polym. Ed. 2005, 16:353-370.
48. Szleifer I. Polymers and proteins interactions at interfaces. Curr. Opin. Solid State Mater. Sci. 1997, 2:337-344.
49. Tinwell H., Ashby J. Genetic toxicity and potential carcinogenicity of taxol. Carcinogenesis 1994, 15:1499-1501.
50. World Health Organization Toxicological Evaluation of Certain Food Additives and Contaminants in Food 1996, World Health Organization, Geneva, (WHO Food Additives Series, 35, pp. 832-852).
51. Ye X., Shao Y., Zhou M., Li J., Cai L. Research on micro-structure and hemo-compatibility of the artificial heart valve surface. Appl. Surf. Sci. 2009, 255:6686-6690.